Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Advertisement
At a median follow-up of 28.6 months, the ORR was 100% and the CR+ CRi rate was 45%.
NX-5948 showed tolerable safety and promising responses in patients with relapsed or refractory CLL or non-Hodgkin lymphoma.
The investigators performed bone marrow assessment at the end of cycle seven.
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Venetoclax plus obinutuzumab was associated with longer PFS compared with chemoimmunotherapy.
More patients with CLL receiving acalabrutinib acquired BTK mutations than those receiving ibrutinib, but did not fare worse.
The regimen even produced benefit in CLL patients who had already been treated with a covalent BTKi.
Venetoclax and obinutuzumab with or without ibrutinib improved PFS versus chemoimmunotherapy or venetoclax and rituximab.
The incidence of bleeding events in patients with CLL receiving BTKis is 26.6 per 100 patients per year.
The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.
Dr. Furqan shared data from a retrospective analysis on patients who received pirtobrutinib prior to CAR T-cell therapy.
Liso-cel was approved in March 2024 by the FDA for patients with relapsed or refractory CLL.
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
A new evaluation of the CLL-IPI revealed that its impact appears diminished in predicting OS in the era of targeted drugs.
The ELCLV3-21 high-risk signature distinguished those with MBL with a high probability of progression.
Using data from CLL long-term cultures, the researchers found that TBX21 expression was induced in CLL cells.
Loss of inhibitor of kappa B epsilon was found to drive NF-κB pathway activity and migration and proliferation of CLL cells.
CAR T-cell therapies effectively treated patients with Richter transformation, an aggressive subtype of CLL.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Alexey V. Danilov, MD, PhDCo-Director of the Toni Stephenson Lymphoma Center | City of Hope National Medical Center
Advertisement
